Department of Medicine, Division of Infectious Diseases, Moores Cancer Center, University of California, San Diego, La Jolla, California 92093, USA.
J Biol Chem. 2011 Apr 1;286(13):11265-74. doi: 10.1074/jbc.M110.182097. Epub 2011 Feb 1.
Hepatitis C virus (HCV) RNA replicates its genome on specialized endoplasmic reticulum modified membranes termed membranous web and utilizes lipid droplets for initiating the viral nucleocapsid assembly. HCV maturation and/or the egress pathway requires host sphingolipid synthesis, which occur in the Golgi. Ceramide transfer protein (CERT) and oxysterol-binding protein (OSBP) play a crucial role in sphingolipid biosynthesis. Protein kinase D (PKD), a serine/threonine kinase, is recruited to the trans-Golgi network where it influences vesicular trafficking to the plasma membrane by regulation of several important mediators via phosphorylation. PKD attenuates the function of both CERT and OSBP by phosphorylation at their respective Ser(132) and Ser(240) residues (phosphorylation inhibition). Here, we investigated the functional role of PKD in HCV secretion. Our studies show that HCV gene expression down-regulated PKD activation. PKD depletion by shRNA or inhibition by pharmacological inhibitor Gö6976 enhanced HCV secretion. Overexpression of a constitutively active form of PKD suppressed HCV secretion. The suppression by PKD was subverted by the ectopic expression of nonphosphorylatable serine mutant CERT S132A or OSBP S240A. These observations imply that PKD negatively regulates HCV secretion/release by attenuating OSBP and CERT functions by phosphorylation inhibition. This study identifies the key role of the Golgi components in the HCV maturation process.
丙型肝炎病毒 (HCV) RNA 在称为膜网络的专门内质网修饰膜上复制其基因组,并利用脂滴起始病毒核衣壳组装。HCV 的成熟和/或出芽途径需要宿主神经鞘脂的合成,这发生在高尔基体中。神经酰胺转移蛋白 (CERT) 和氧化固醇结合蛋白 (OSBP) 在神经鞘脂生物合成中发挥关键作用。蛋白激酶 D (PKD) 是一种丝氨酸/苏氨酸激酶,它被招募到反式高尔基体网络,在那里通过磷酸化调节几个重要介质来影响囊泡向质膜的运输。PKD 通过磷酸化其各自的 Ser(132)和 Ser(240)残基(磷酸化抑制)来减弱 CERT 和 OSBP 的功能。在这里,我们研究了 PKD 在 HCV 分泌中的功能作用。我们的研究表明,HCV 基因表达下调了 PKD 的激活。通过 shRNA 或药理学抑制剂 Gö6976 抑制 PKD 可增强 HCV 分泌。过表达组成型激活形式的 PKD 可抑制 HCV 分泌。PKD 的抑制作用可通过外源性表达非磷酸化丝氨酸突变型 CERT S132A 或 OSBP S240A 来克服。这些观察结果表明,PKD 通过磷酸化抑制来减弱 OSBP 和 CERT 的功能,从而负调控 HCV 的分泌/释放。本研究确定了高尔基体成分在 HCV 成熟过程中的关键作用。